Garg N, Khunger M, Gupta A, et al.-Optimal management of hereditary hemorrhagic telangiectasia. J Blood Med, 2014, 5, 191-206
Dakeishi M, Shioya T, Wada Y, et al.-Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Hum Mut, 2002, 19, 140-8.
Westermann CJ, Rosina AF, Vries VD, et al.-The prevalence and manifestations of hereditary hemorrhagic telangiectasia in the Afro-Caribbean population of the Netherlands Antilles: a family screening. Am J Med Genet, 2003, 116, 324-8.
Lesca G, Genin E, Blachier C, et al.-Hereditary hemorrhagic telangiectasia: evidence for regional founder effects of ACVRL1 mutations in French and Italian patients. Eur J Hum Genet, 2008, 16, 742-9.
McAllister KA, Grogg KM, Johnson DW, et al.-Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type Nat Genet, 1994, 8, 345-51.
Lesca G, Plauchu H, Coulet F, et al.-Molecular screening of ALK1/ACVRL1 and ENG genes in hereditary hemorrhagic telangiectasia in France. Hum Mutat, 2004, 23, 289-99.
Bourdeau A, Cymerman U, Paquet ME, et al.-Endoglin expression is reduced in normal vessels but still detectable in arteriovenous malformations of patients with hereditary haemorrhagic telangiectasia type Am J Pathol, 2000, 156, 911-23.
Berg JN, Gallione CJ, Stenzel TT, et al.-The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary haemorrhagic telangiectasia type Am J Hum Genet, 1997, 61, 60-7.
Pece-Barbara N, Cymerman U, Vera S, et al.-Expression analysis of four endoglin missense mutations suggests that haploinsufficiency is the predominant mechanism for hereditary hemorrhagic telangiectasia type Hum Mol Genet, 1999, 8, 2171-81.
Gallione CJ, Repetto GM, Legius E, et al.-A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet, 2004, 363, 852-915.
Gallione C, Aylsworth A, Beis J, et al.-Overlapping spectra of SMAD4 mutations in juvenile polyposis (JP) and JP-HHT syndrome. Am J Med Genet A, 2010, 152A, 333-9.
University of Utah, Department of Pathology.-HHT Mutation Database, http://www.hhtmutation.org. Consultation du 21 décembre 2014.
Plauchu H, de Chadavian JP, Bideau A, et al.-Agerelated clinical profile of hereditary hemorrhagic in an epidemiologically recruited population. Am J Med Genet, 1989, 32, 291.
Stabile Ianora AA, Memeo M, Sabba C, et al.-Hereditary hemorrhagic telangiectasia: multidetector row helical CT assessment of hepatic involvement. Radiology, 2004, 230, 350-9.
Buscarini E, Danesino C, Olivieri C, et al.-A. Liver involvement in hereditary haemorrhagic telangiectasia of Rendu-Osler disease. Dig Liv, 2005, 37, 635-45.
Buscarini E, Plauchu H, Garcia Tsao G, et al.-Liver involvement in hereditary hemorrhagic telangiectasia: consensus recommendations. Liver Int, 2006, 26, 1040-6.
Garcia-Tsao G, Korzenik JR, Young L, et al.-Liver disease in patient with hereditary hemorrhagic telangiectasia. N Engl J Med, 2000, 343, 931.
Ocran K, Rickes S, Heukamp I, et al.-Sonographic findings in hepatic involvement of hereditary haemorrhagic telangiectasia. Ultraschall Med, 2004, 25, 191-194.
Sabba C, Pasculli G, Lenato GM, et al.-Here-ditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutationcarriers. J Thromb Haemost, 2007, 5, 1149-57.
Gincul R, Lesca G, Gelas-Dore B, et al.-Evaluation of previously nonscreened hereditary hemorrhagic telangiectasia patients shows frequent liver involvement and early cardiac consequences. Hepatology, 2008, 48, 1377-9.
Buonamico P, Suppressa P, Lenato GM, et al.-Liver involvement in a large cohort of patients with hereditary hemorrhagictelangiectasia: echo-color-Doppler vs. multislice computed tomography study. J Hepatol, 2008, 48, 811-20.
Shovlin CL, Guttmacher AE, Buscarini E, et al.-Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet, 2000, 91, 66-67.
Jameson JJ, Cave DR.-Hormonal and antihormonal therapy for epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope, 2004, 114, 705-709.
Dupuis-Girod S, Chesnais AL, Ginon I, et al.-Longterm outcome of patients with hereditary hemorrhagic telangiectasiaand severe hepatic involvement after orthotopic liver transplantation: a single-center study. Liver Transpl, 2010, 16, 340-7.
Bose P, Holter JL, Selby GB.-Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med, 2009, 360, 2143.
Dupuis-Girod S, Ginon I, Saurin JC, et al.-Bevacizumab in patients with hereditary hemorrhagic telangiectasia andsevere hepatic vascular malformations and high cardiac output. JAMA, 2012, 307, 948-55.
Shovlin CL, Jackon JE, Bamford KB, et al.-Primary determinants of ischaemic stroke/brain abscess risks are independent of severity of arteriovenous malformations in hereditary haemorrhagic telangiectasia. Thorax, 2008, 63, 259.
Devlin HL, Hosman AE, Shovlin CL.-Antiplatelet and anticoagulant agents in hereditary hemorrhagic telangiectasia. N Engl J Med, 2013, 368, 876-878.
Hosman AE, Devlin HL, Silva MB, et al.-Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls. Orphanet J Rare Dis, 2013, 8, 19.
